Phase Ib Study of Efsubaglutide Alfa Injection in Obese Adolescents
ClinicalTrials.gov · NCT07693426 · Registry updated: 2026-07-30
- Condition / research focus
- Adolescence Obesity
- Sponsor
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
- Countries with listed sites
- China
- Registry dates and results
- Start: 2026-07-16. Completion: 2027-08-31 (may be estimated). No results posted in this registry response.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Efsubaglutide Alfa 5 mg QW (drug)
- Efsubaglutide Alfa 10 mg QW (drug)
- Efsubaglutide Alfa 20 mg QW (drug)
- Efsubaglutide Alfa placebo (drug)
Where the study takes place — 5 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Beijing Chaoyang Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Site recruitment: Recruiting - Wuhan Central Hospital
Wuhan, Hubei, China
Site recruitment: Not yet recruiting - Shengjing Hospital, China Medical University
Shenyang, Liaoning, China
Site recruitment: Not yet recruiting - Qilu Hospital, Shandong University
Jinan, Shandong, China
Site recruitment: Not yet recruiting - Qilu Second Hospital, Shandong University
Jinan, Shandong, China
Site recruitment: Recruiting

